Cyclophosphamide for severe lupus nephritis: where are we now?
作者信息
Mok Chi Chiu
出版信息
Arthritis Rheum. 2004 Dec;50(12):3748-50. doi: 10.1002/art.20667.
PMID:15593210
Abstract
摘要
相似文献
1
Cyclophosphamide for severe lupus nephritis: where are we now?
Arthritis Rheum. 2004 Dec;50(12):3748-50. doi: 10.1002/art.20667.
2
Choosing treatment for proliferative lupus nephritis.
Arthritis Rheum. 2002 Aug;46(8):1981-3. doi: 10.1002/art.10466.
3
[Cyclophosphamide-induced lupus flare in diffuse proliferative lupus nephropathy].
Nefrologia. 2011;31(2):231-3. doi: 10.3265/Nefrologia.pre2010.Nov.10674.
4
Efficacy of low-dose versus high-dose cyclophosphamide in lupus nephritis: comment on the article by Houssiau et al.
Arthritis Rheum. 2003 May;48(5):1466; author reply 1466-7. doi: 10.1002/art.10967.
5
This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.
Rheumatology (Oxford). 2005 Mar;44(3):398-401. doi: 10.1093/rheumatology/keh440. Epub 2004 Oct 19.
6
[Plasmapheresis in a case of necessary discontinuation of cyclophosphamide in the treatment of severe lupus nephritis].
Pol Merkur Lekarski. 2004 Aug;17(98):162-4.
7
Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Arthritis Rheum. 2007 Mar;56(3):924-37. doi: 10.1002/art.22449.
8
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.
J Pharmacol Exp Ther. 2009 Feb;328(2):371-7. doi: 10.1124/jpet.108.142711. Epub 2008 Nov 7.
9
Treatment and outcome of lupus nephritis at the turn of the millennium.
J Assoc Physicians India. 1999 Sep;47(9):857-61.
10
Cyclophosphamide in lupus nephritis.
Lupus. 2005;14(1):53-8. doi: 10.1191/0961203305lu2060oa.
Zotero 插件